Literature DB >> 27493486

Effect of Daisaikoto on Expressions of SIRT1 and NF-kappaB of Diabetic Fatty Liver Rats Induced by High-Fat Diet and Streptozotocin.

Weibin Qian1, Xinrui Cai2, Xinying Zhang3, Yingying Wang4, Qiuhai Qian3, Junichi Hasegawa5.   

Abstract

BACKGROUND: Daisaikoto (DSKT), a classical traditional Chinese herbal formula, has been used for treating digestive diseases for 1800 years in China. Therefore, in this study, we are going to investigate the effect of DSKT on diabetic fatty liver rats induced by a high-fat diet and streptozotocin (STZ), and the effects of DSKT on silent mating type information regulation 2 homolog 1 (SIRT1) and nuclear factor kappa B (NF-kappaB).
METHODS: Diabetic fatty liver rat model was selected to establish a high-fat diet and STZ. Sixty Wistar rats were divided into six groups (n = 10): control group, high-fat diet + STZ group, simvastatin treatment group, DSKT low dose, medial dose and high dose treatment groups. After 8 weeks of drug intervention, body and liver weights, blood chemistry, blood glucose and insulin were examined. The expressions of sirtuin 1 and NF-kappaB in the liver were observed by RT-PCR and immunohistochemistry, respectively.
RESULTS: A high-fat diet increased body, liver weights, and serum cholesterol concentrations. Intraperitoneal injection of STZ increased blood glucose and decreased body weights. DSKT improved them. Homeostasis model assessment-estimated insulin resistance (HOMA-IR) indices were increased in the high-fat diet groups. DSKT improved them too. In histological examinations of the liver, we observed a significant improvement after treatment. Immunostaining expression of NF-kappaB in the liver was improved by DSKT and simvastatin. The mRNA expressions of SIRT1 in the liver were increased by DSKT and simvastatin.
CONCLUSION: We have demonstrated that DSKT is capable of reversing dyslipidemia and insulin resistance induced by a high-fat diet and STZ. High dose DSKT reveals a stronger effect than simvastatin on the expressions of SIRT1 and NF-kappaB. Furthermore, DSKT has shown a strong dose-depended protective effect on diabetic fatty liver.

Entities:  

Keywords:  daisaikoto; diabetes; fatty liver; nuclear factor kappa B; silent mating type information regulation 2 homolog 1

Year:  2016        PMID: 27493486      PMCID: PMC4973021     

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  34 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

2.  Risk of adverse events with fibrates.

Authors:  Alawi A Alsheikh-Ali; Jeffrey T Kuvin; Richard H Karas
Journal:  Am J Cardiol       Date:  2004-10-01       Impact factor: 2.778

3.  Inhibitory effects of Dai-saiko-to (Da-Chai-Hu-Tang) on the progression of atherosclerotic lesions in Kurosawa and Kusanagi-hypercholesterolemic rabbits.

Authors:  A Iizuka; O T Iijima; F Yoshie; B Makino; S Amagaya; Y Komatsu; K Kondo; A Matsumoto; H Itakura
Journal:  J Ethnopharmacol       Date:  1998-12       Impact factor: 4.360

Review 4.  Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Authors:  Luca Miele; Alessandra Forgione; Giovanni Gasbarrini; Antonio Grieco
Journal:  Transl Res       Date:  2007-03       Impact factor: 7.012

5.  Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.

Authors:  Sawsan Zaitone; Neven Hassan; Naglaa El-Orabi; El-Sayed El-Awady
Journal:  Eur J Pharmacol       Date:  2011-04-30       Impact factor: 4.432

Review 6.  SIRT1 as a therapeutic target in inflammaging of the pulmonary disease.

Authors:  Irfan Rahman; Vuokko L Kinnula; Vera Gorbunova; Hongwei Yao
Journal:  Prev Med       Date:  2011-12-08       Impact factor: 4.018

7.  Carbon monoxide protects against hepatic ischemia/reperfusion injury by modulating the miR-34a/SIRT1 pathway.

Authors:  Hyo Jeong Kim; Yeonsoo Joe; Jae Kyoung Yu; Yingqing Chen; Sun Oh Jeong; Nithya Mani; Gyeong Jae Cho; Hyun-Ock Pae; Stefan W Ryter; Hun Taeg Chung
Journal:  Biochim Biophys Acta       Date:  2015-04-23

8.  [Relationship of socioeconomic status and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus].

Authors:  Guoyu Jia; Xuefen Li; Lu Wang; Qiang Li; Li Yang; Nali Li; Fusheng Di
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2015-10

9.  Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes.

Authors:  Debmalya Sanyal; Pradip Mukherjee; Moutusi Raychaudhuri; Sujoy Ghosh; Satinath Mukherjee; Subhankar Chowdhury
Journal:  Indian J Endocrinol Metab       Date:  2015 Sep-Oct

10.  Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus.

Authors:  Guoyu Jia; Fusheng Di; Qipeng Wang; Jinshuang Shao; Lei Gao; Lu Wang; Qiang Li; Nali Li
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240

View more
  4 in total

1.  Daisaikoto improves fatty liver and obesity in melanocortin-4 receptor gene-deficient mice via the activation of brown adipose tissue.

Authors:  Shinichi Morita; Akira Sakamaki; Kyutaro Koyama; Osamu Shibata; Takashi Owaki; Chiyumi Oda; Atsushi Kimura; Taiki Nakaya; Katsuya Ohbuchi; Miwa Nahata; Naoki Fujitsuka; Norihiro Sakai; Hiroyuki Abe; Kenya Kamimura; Shuji Terai
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

2.  The efficacy and safety of dachaihu decoction in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis.

Authors:  Zehua Zhang; Yulin Leng; Xiaoxu Fu; Chan Yang; Hongyan Xie; Haipo Yuan; Qingzhi Liang; Hong Gao; Chunguang Xie
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

3.  Targeted bile acid profiles reveal the liver injury amelioration of Da-Chai-Hu decoction against ANIT- and BDL-induced cholestasis.

Authors:  YueHua Zhou; YunZhong Zhou; YiFei Li; Wei Sun; ZhaoLong Wang; Long Chen; Ye He; XiaoLong Niu; Jialiang Chen; Guangtao Yao
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

Review 4.  The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism.

Authors:  Sha Li; Yu Xu; Wei Guo; Feiyu Chen; Cheng Zhang; Hor Yue Tan; Ning Wang; Yibin Feng
Journal:  Front Pharmacol       Date:  2020-03-24       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.